AGM Statement

    RNS Number : 5222D
  Medical Marketing Int'l Group PLC
  17 September 2008
   

    AGM Statement

    Wednesday 17 September 2008 - Phil Cartmell, Non-executive Chairman of Medical Marketing International Group plc ("MMI" or the
"Company") (AIM:MMG), the life sciences company focused on the development of drugs for cancer, will today provide a development update on
the Company's cancer vaccines and ruthenium chemotherapies at the Company's Annual General Meeting and make the following statement.

    Cancer vaccines
    A commercial prostate cancer vaccine ("GVX 3322") has now been assembled and the DNA sequence verified.  Immunogenicity testing will
commence shortly and will compare, in preclinical in vivo models, the immune responses obtained with GVX 3322 with the academic vaccine used
in clinical trials to date. Results will be available during the final quarter of this calendar year and, if positive, the Company will
progress its preparations for the commencement of a Phase II trial.

    Ruthenium chemotherapies
    The patent portfolio covering MMI's ruthenium based anti-cancer compounds has been strengthened further following the notification
allowance of a third EU patent. Efficacy testing of ONCO 4417 against a lung cancer in vivo model is in progress and the results will be
made available during the final quarter of this calendar year. Work has also commenced on elucidating the mechanism by which ONCO 4417
instigates cancer cell death and to understand the type of DNA damage caused by these compounds. 

    We are pleased to report the progress that we have made with our cancer vaccines and ruthenium chemotherapies. The proceeds from the
recent placing have enabled us to embark on the next phase of development for our two lead oncology products and we remain focused on
reaching our objective of creating clear value for our shareholders.


    Enquiries:

 Medical Marketing International Group plc
 Phil Cartmell, Non-executive Chairman      Tel: [phone]
 Mark Burton, Chief Technical Officer
 Rob Sprawson, Chief Financial Officer
  
 FinnCap
 Sam Smith/Charlie Cunningham                Tel: [phone]

 Financial Dynamics
 David Yates/Emma Thompson                   Tel: [phone]

    About MMI
    Medical Marketing International Group plc ("MMI") is a life sciences company that identifies, acquires and develops world-class
compounds and technologies for the treatment of cancer. The Company manages the preclinical and early clinical development of drug
candidates before pursuing licensing partners to manage late-stage development. Please visit www.mmigroup.co.uk for further information.

    Notwithstanding the inclusion on this release by MMI of a website address and/or another electronic address, MMI does not accept any
notices or any other documents or communication via its website or other electronic address. All such notices, documents or communication
shall be in hard copy format only. Accordingly the provisions of section 333 Companies Act 2006 allowing persons to communicate with MMI
electronically shall not apply to MMI.

    -ends-


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
AGMSFESUMSASESU